Matches in Wikidata for { <http://www.wikidata.org/entity/Q63582885> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q63582885 description "clinical trial" @default.
- Q63582885 description "ensayu clínicu" @default.
- Q63582885 description "klinisch onderzoek" @default.
- Q63582885 description "клінічне випробування" @default.
- Q63582885 name "TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery" @default.
- Q63582885 type Item @default.
- Q63582885 label "TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery" @default.
- Q63582885 prefLabel "TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery" @default.
- Q63582885 P1132 Q63582885-AC3B9EC1-2705-4E31-94E5-11105B4E136C @default.
- Q63582885 P1476 Q63582885-101C15EC-A02A-4391-BB00-3DD59F052537 @default.
- Q63582885 P2899 Q63582885-CDCACF88-72A7-414F-B618-8F3960DFBC58 @default.
- Q63582885 P3098 Q63582885-649E2117-61A9-4615-A9F9-83C240820276 @default.
- Q63582885 P31 Q63582885-B7F1F569-4C8E-4BD0-9759-310EF6BA4A92 @default.
- Q63582885 P4844 Q63582885-1672377C-7ED0-42EB-8E94-3CC62D5B63E6 @default.
- Q63582885 P4844 Q63582885-544E6759-FE13-4DE7-B3C5-5909078E2F2E @default.
- Q63582885 P4844 Q63582885-567B5C48-2CDB-4356-B0D6-968270035514 @default.
- Q63582885 P4844 Q63582885-65E31EEA-5EB7-4490-9E9A-62DF006F6DD1 @default.
- Q63582885 P580 Q63582885-46237B3C-A195-4DAB-9E85-22E062685F5D @default.
- Q63582885 P582 Q63582885-F6BDEB9B-823D-4556-8D19-18657B3BC242 @default.
- Q63582885 P6099 Q63582885-7C9765D6-878E-4A08-84DE-9BDA24EDBD58 @default.
- Q63582885 P6099 Q63582885-C0DE8925-5132-4C2B-9B11-431F94C3571D @default.
- Q63582885 P6153 Q63582885-A465BACD-9B36-46C1-B9AD-00FEE79219B7 @default.
- Q63582885 P8363 Q63582885-C09E8316-3BA9-4158-96A5-243369C7F03C @default.
- Q63582885 P1132 "+67" @default.
- Q63582885 P1476 "Docetaxel Plus Atezolizumab Plus Herceptin SC and Pertuzumab (TAHP) for Patients With HER2-positive Early Breast Cancer and Subsequent Atezolizumab Plus Herceptin SC and Pertuzumab (AHP) Adjuvant tHerapy After Surgery" @default.
- Q63582885 P2899 "+18" @default.
- Q63582885 P3098 "NCT03881878" @default.
- Q63582885 P31 Q30612 @default.
- Q63582885 P4844 Q1998021 @default.
- Q63582885 P4844 Q20707748 @default.
- Q63582885 P4844 Q412616 @default.
- Q63582885 P4844 Q420436 @default.
- Q63582885 P580 "2019-05-27T00:00:00Z" @default.
- Q63582885 P582 "2022-10-31T00:00:00Z" @default.
- Q63582885 P6099 Q42824440 @default.
- Q63582885 P6099 Q5452194 @default.
- Q63582885 P6153 Q624119 @default.
- Q63582885 P8363 Q78089383 @default.